---
title: Sulodexide in Controlling the Recurrence of Psoriasis
nct_id: NCT06982196
overall_status: ENROLLING_BY_INVITATION
phase: PHASE3
sponsor: Xijing Hospital
study_type: INTERVENTIONAL
primary_condition: Psoriasis (PsO)
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06982196.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06982196"
ct_last_update_post_date: 2025-05-21
last_seen_at: "2026-05-12T06:59:38.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Sulodexide in Controlling the Recurrence of Psoriasis

**Official Title:** Multicenter, Randomized, Double-blinded，Controlled Clinical Study to Evaluate the Efficacy and Safety of Sulodexide in Controlling the Recurrence of Psoriasis

**NCT ID:** [NCT06982196](https://clinicaltrials.gov/study/NCT06982196)

## Key Facts

- **Status:** ENROLLING_BY_INVITATION
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 160
- **Lead Sponsor:** Xijing Hospital
- **Conditions:** Psoriasis (PsO), Randomised Controlled Trial
- **Start Date:** 2025-04-20
- **Completion Date:** 2027-12-31
- **CT.gov Last Update:** 2025-05-21

## Brief Summary

This is a multicenter, randomized, double-blinded，controlled clinical trial. The purpose of the study is to evaluate the efficacy and safety of Sulodexide versus placebo in preventing psoriasis recurrence in patients with plaque psoriasis who have discontinued biologic therapy after achieving clinical cure.

## Detailed Description

It was planned to include 160 patients with psoriasis vulgaris who met the inclusion criteria for discontinuation of biologics after reaching the standard of treatment and were randomised in a 1:1 ratio to receive oral treatment with sulodexide soft capsules or placebo capsules, respectively.

1. Sulodexide group： Starting after the last injection of secukinumab, oral treatment with sulodexide soft capsule (Alpha Weissmann Pharmaceuticals, Italy, approval number H20140119, specification 250 LSU) was given as 1 tab bid for 120 days or discontinued after judged to be a relapse;
2. Control group: Oral treatment with placebo capsule, 1 tab bid starting after the last injection of secukinumab, discontinued after 120 days of continuous oral administration or judged to be discontinued for relapse.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Age is 18-65 years old and gender is not limited;
2. Clinical diagnosis consistent with moderate to severe plaque psoriasis;
3. After receiving standardised treatment with strychnicolizumab for 3 months to achieve complete clearing of skin lesions (in accordance with PASI 100 or PGA 0), and then continuing the treatment for 6 months without symptomatic relapse to satisfy the criteria for discontinuation of the drug and discontinuing strychnicolizumab (refer to the recommendations of 'Guidelines for the treatment of psoriasis with biologics in China (2021 edition)');
4. Voluntarily participate in the study and sign the informed consent form before the start of the study.

Exclusion Criteria:

1. Suffering from severe systemic or localised infections within the last 6 months;
2. Those with bleeding tendency or suffering from bleeding disorders;
3. The presence of malignant tumours, or postoperative tumour patients and those at high risk of tumours;
4. Have received or currently require treatment with other anticoagulant drugs such as sulodexide drugs within the last 9 months (e.g. argatroban, bivalirudin, dabigatran etexilate, desirudin, lepirudin, aspirin, etc.);
5. Treatment with other biological agents within the last 9 months;
6. Highly allergic or with a history of severe allergies; allergy to heparin or heparin analogues; or known/suspected allergy to one of the components of the investigational drug;
7. Infection with other diseases such as Human Immunodeficiency Virus (HIV);
8. Serious, progressive, uncontrolled disorders of vital organs and systems (including cardiovascular, hepatic, pulmonary, and renal) and other diseases that, in the opinion of the investigator, are not suitable for participation in the study in combination;
9. Clinically significant abnormal values on screening tests as determined by the investigator;
10. Pregnant women or women of childbearing potential who intend to become pregnant or breastfeeding during the trial period;
11. A positive serum or urine pregnancy test in a female of childbearing potential during the Screening Period;
12. Currently participating in another clinical study or have participated in another clinical study within 3 months;
13. Known presence of alcoholism, drug dependence, or psychiatric disorders
14. Known or suspected to be unable to complete the trial due to poor adherence;
15. Who, in the judgement of the investigator, are unsuitable for participation in this clinical study.
```

## Arms

- **Sulodexide Group** (EXPERIMENTAL) — Participants in this group will receive oral sulodexide soft capsules (manufactured by Alfa Wassermann, Italy; approval number H20140119, specification 250 LSU) after discontinuing secukinumab. The dosing regimen is 1 capsule twice daily for 120 consecutive days or until psoriasis relapse is confirmed. Sulodexide, a vascular protective agent, aims to prolong psoriasis recurrence by improving vascular endothelial barrier function. During the study, disease relapse (assessed via PASI scores) and safety indicators (e.g., adverse events, laboratory tests) will be regularly monitored.
- **Placebo Comparator Group** (PLACEBO_COMPARATOR) — Participants in this group will receive matching placebo capsules orally after discontinuing secukinumab. The dosing regimen is 1 capsule twice daily for 120 consecutive days or until psoriasis relapse is confirmed. The placebo capsules are identical in appearance and packaging to the active sulodexide capsules but contain no active pharmaceutical ingredients. This group serves as a control to evaluate the efficacy of sulodexide in delaying psoriasis recurrence. Disease relapse (assessed via PASIscores) and safety indicators (e.g., adverse events, laboratory tests) will be monitored at the same intervals as the experimental group.

## Interventions

- **Sulodexide** (DRUG) — Sulodexide group：Starting after the last injection of secukinumab, oral treatment with sulodexide soft capsule (Alpha Weissmann Pharmaceuticals, Italy, approval number H20140119, specification 250 LSU) was given as 1 tab bid for 120 days or discontinued after judged to be a relapse.
- **Placebo** (DRUG) — Control group: Oral treatment with placebo capsule, 1 tab bid starting after the last injection of secukinumab, discontinued after 120 days of continuous oral administration or judged to be discontinued for relapse.

## Primary Outcomes

- **Time of appearance of the first psoriatic skin lesion** _(time frame: 1 year)_ — This outcome measures the duration (in days) from the start of the study intervention (sulodexide or placebo) until the first identifiable recurrence of a characteristic psoriatic skin lesion in participants who had previously achieved complete clearance (PASI 100) with secukinumab therapy.

## Secondary Outcomes

- **Psoriasis lesion size and severity index score[PASI]** _(time frame: 1 year)_
- **Dermatological Quality of Life Index[DLQI]** _(time frame: 1 year)_
- **Self-Rating Anxiety Scale** _(time frame: 1 year)_
- **Self-Rating Depression Scale** _(time frame: 1 year)_
- **Adverse Events [AEs]** _(time frame: 1 year)_

## Locations (1)

- xjjing Hospital, Xi'an, China

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.xjjing hospital|xi'an||china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06982196.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06982196*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*